RU2122426C1 - Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина - Google Patents

Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина Download PDF

Info

Publication number
RU2122426C1
RU2122426C1 RU94045932A RU94045932A RU2122426C1 RU 2122426 C1 RU2122426 C1 RU 2122426C1 RU 94045932 A RU94045932 A RU 94045932A RU 94045932 A RU94045932 A RU 94045932A RU 2122426 C1 RU2122426 C1 RU 2122426C1
Authority
RU
Russia
Prior art keywords
histidine
growth hormone
derivative
hgh
crystals
Prior art date
Application number
RU94045932A
Other languages
English (en)
Russian (ru)
Other versions
RU94045932A (ru
Inventor
Хольмегорд Серенсен Ханс
Скривер Ларс
Рассинг Холгорд Анни
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU94045932A publication Critical patent/RU94045932A/ru
Application granted granted Critical
Publication of RU2122426C1 publication Critical patent/RU2122426C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU94045932A 1991-12-20 1992-12-16 Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина RU2122426C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK2046/91 1991-12-20
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
DK1364/92 1992-11-10

Publications (2)

Publication Number Publication Date
RU94045932A RU94045932A (ru) 1997-04-20
RU2122426C1 true RU2122426C1 (ru) 1998-11-27

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94045932A RU2122426C1 (ru) 1991-12-20 1992-12-16 Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина

Country Status (24)

Country Link
EP (2) EP0618807B1 (fr)
JP (2) JP2950617B2 (fr)
KR (1) KR100266502B1 (fr)
AT (2) ATE227583T1 (fr)
AU (1) AU667503B2 (fr)
BG (1) BG63075B1 (fr)
CA (1) CA2125855C (fr)
CZ (1) CZ283361B6 (fr)
DE (3) DE10399015I1 (fr)
DK (1) DK0618807T3 (fr)
ES (2) ES2185625T3 (fr)
FI (1) FI115116B (fr)
HU (1) HUT69402A (fr)
IL (1) IL104152A (fr)
MX (1) MX9207374A (fr)
NL (1) NL300126I1 (fr)
NO (1) NO942300L (fr)
NZ (1) NZ246556A (fr)
PT (1) PT618807E (fr)
RO (1) RO111990B1 (fr)
RU (1) RU2122426C1 (fr)
SK (1) SK279641B6 (fr)
UA (1) UA41502C2 (fr)
WO (1) WO1993012812A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2592671C2 (ru) * 2010-09-21 2016-07-27 Ферринг Б.В. Улучшенный способ получения рекомбинантного человеческого гормона роста
RU2803237C2 (ru) * 2018-10-26 2023-09-11 Ново Нордиск А/С Стабильные композиции на основе семаглутида и их варианты применения

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
ES2139081T3 (es) * 1994-06-17 2000-02-01 Applied Res Systems Ars Holding N V Composiciones farmaceuticas que contienen la hormona humana del crecimiento.
IL114030A (en) * 1994-06-27 2000-08-13 Hayashibara Biochem Lab Saccharide composition with a lesser reducibility its preparation and compositions containing it
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
EP0805689A1 (fr) * 1995-01-13 1997-11-12 Novo Nordisk A/S Formulation pharmaceutique stabilisee comprenant une hormone de croissance et lys-x
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
CA2309818C (fr) * 1997-11-12 2009-05-05 Alza Corporation Formulations pharmaceutiques tamponnees a administration transdermique par electrotransport
EP2311436A1 (fr) * 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Cristaux de protéines stabilisées, formulations renfermant lesdits cristaux et leurs procèdes de fabrication
KR20090007504A (ko) * 2000-02-24 2009-01-16 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
AU2002339115B2 (en) 2001-05-18 2007-03-15 Dupont Nutrition Biosciences Aps Method of preparing a dough with an enzyme
WO2004060310A2 (fr) 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Cristaux d'hormone de croissance humaine et procedes de preparation correspondants
NZ571243A (en) * 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
CN101818177A (zh) 2004-07-16 2010-09-01 丹尼斯科公司 脂肪分解酶及其在食品工业中的应用
JP5201992B2 (ja) * 2004-12-15 2013-06-05 バイオビトラム・アクテイエボラーグ（パブリツク） ケラチノサイト増殖因子の治療用製剤
US7816320B2 (en) * 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
AU2006286486A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
WO2007033427A1 (fr) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation de peptides comprenant des acides aminés basiques
WO2007074133A2 (fr) 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprenant de l'insuline acylée et du zinc, et procédés de préparation de celles-ci
EP2040757A2 (fr) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG Nouveaux conjugués de protéines et leurs procédés de préparation
WO2008076819A2 (fr) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Compositions d'hormone de croissance humaine
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
EP3608330B1 (fr) * 2008-12-16 2022-11-09 Genzyme Corporation Intermédiaires synthétiques utiles dans la préparation des conjugués oliogosaccharide-protéine
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
EP2663647A4 (fr) 2011-01-14 2015-08-19 Redwood Bioscience Inc Immunoglobulines polypeptidiques à marquage aldéhydique et leur méthode d'utilisation
ES2715028T3 (es) 2012-06-05 2019-05-31 Neuroderm Ltd Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3388089B1 (fr) * 2015-12-10 2022-05-18 Menicon Co., Ltd. Composition peptidique
CA3019398A1 (fr) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Conjugues d'anticorps et methodes de fabrication et d'utilisation de ceux-ci
JP7449243B2 (ja) * 2018-05-25 2024-03-13 ドクター レディズ ラボラトリーズ リミテッド 安定な融合タンパク質製剤
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2022197963A1 (fr) * 2021-03-19 2022-09-22 Pfizer Inc. Compositions d'hormone de croissance à action prolongée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0374120A3 (fr) * 1988-12-13 1991-07-31 Monsanto Company Composition pour la libération contrôlée des polypeptides
DK168790D0 (fr) * 1990-07-13 1990-07-13 Novo Nordisk As

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2592671C2 (ru) * 2010-09-21 2016-07-27 Ферринг Б.В. Улучшенный способ получения рекомбинантного человеческого гормона роста
RU2803237C2 (ru) * 2018-10-26 2023-09-11 Ново Нордиск А/С Стабильные композиции на основе семаглутида и их варианты применения

Also Published As

Publication number Publication date
AU3344693A (en) 1993-07-28
NO942300L (no) 1994-08-19
EP1197222A3 (fr) 2004-02-04
RU94045932A (ru) 1997-04-20
EP0618807B1 (fr) 2002-11-13
BG98806A (bg) 1995-02-28
CA2125855C (fr) 2008-05-13
UA41502C2 (uk) 2001-09-17
RO111990B1 (ro) 1997-04-30
JPH11315031A (ja) 1999-11-16
BG63075B1 (bg) 2001-03-30
PT618807E (pt) 2003-03-31
WO1993012812A1 (fr) 1993-07-08
NL300126I1 (nl) 2003-07-01
DK0618807T3 (da) 2003-03-03
CZ150794A3 (en) 1995-01-18
ES2291264T3 (es) 2008-03-01
DE69232847D1 (de) 2002-12-19
CZ283361B6 (cs) 1998-03-18
IL104152A (en) 1998-06-15
JPH07502516A (ja) 1995-03-16
NO942300D0 (no) 1994-06-17
FI942906A0 (fi) 1994-06-17
AU667503B2 (en) 1996-03-28
JP2950617B2 (ja) 1999-09-20
EP1197222A2 (fr) 2002-04-17
DE69232847T2 (de) 2003-09-11
SK75494A3 (en) 1995-03-08
DE10399015I1 (de) 2012-05-03
MX9207374A (es) 1993-07-01
NZ246556A (en) 1996-03-26
FI115116B (fi) 2005-03-15
DE69233704D1 (de) 2007-09-13
SK279641B6 (sk) 1999-01-11
HU9401832D0 (en) 1994-09-28
ES2185625T3 (es) 2003-05-01
ATE368472T1 (de) 2007-08-15
HUT69402A (en) 1995-09-28
DE10399015I2 (de) 2008-08-07
DE69233704T2 (de) 2008-05-21
ATE227583T1 (de) 2002-11-15
IL104152A0 (en) 1993-05-13
KR100266502B1 (ko) 2000-09-15
EP1197222B1 (fr) 2007-08-01
EP0618807A1 (fr) 1994-10-12
FI942906A (fi) 1994-06-17
CA2125855A1 (fr) 1993-07-08

Similar Documents

Publication Publication Date Title
RU2122426C1 (ru) Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина
US5849700A (en) Pharmaceutical formulation
US5849704A (en) Pharmaceutical formulation
CA2252535C (fr) Formulation pharmaceutique contenant une hormone de croissance, un acide amine et un detergent non ionique
RU2098130C1 (ru) Фармацевтический препарат гормона роста и его стабилизатор
US5705482A (en) Pharmaceutical formulation
CA2226523A1 (fr) Formulation pharmaceutique stabilisee comprenant une hormone de croissance pre-traitee avec des ions zinc et facultativement lysine ou calcium
US8841252B2 (en) Pharmaceutical formulation
US5654278A (en) Composition and method comprising growth hormone and leucine
JP4064454B2 (ja) 成長ホルモンおよびイソロイシンを含んでなる医薬製剤
JP4064453B2 (ja) 成長ホルモンおよびバリンを含んでなる医薬製剤
US6022858A (en) Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
EP0785797B1 (fr) Formulation pharmaceutique comportant une hormone de croissance et de la leucine
PL171356B1 (pl) Sposób wytwarzania kryształów hormonu wzrostu lub pochodnych hormonu wzrostu i histydyny lub pochodnej histydyny
MXPA98008786A (en) A pharmaceutical formulation containing a growth hormone, an amino acid and a non-ion detergent

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20111220